Alina M. Allen, Vijay H. Shah, Terry M. Therneau, Sudhakar K. Venkatesh, Taofic Mounajjed, Joseph J. Larson, Kristin C. Mara, Phillip J. Schulte, Todd A. Kellogg, Michael L. Kendrick, Travis J. McKenzie, Suzanne M. Greiner, Jiahui Li, Kevin J. Glaser, Michael L. Wells, Jun Chen, Richard L. Ehman, Meng Yin – 24 December 2018 – The lack of reliable, noninvasive methods to diagnose early nonalcoholic steatohepatitis (NASH) is a major unmet need.

Changqing Xie, Austin G. Duffy, Donna Mabry‐Hrones, Bradford Wood, Elliot Levy, Venkatesh Krishnasamy, Javed Khan, Jun S. Wei, David Agdashian, Manoj Tyagi, Vineela Gangalapudi, Suzanne Fioravanti, Melissa Walker, Victoria Anderson, David Venzon, William D. Figg, Milan Sandhu, David E. Kleiner, Maria Pia Morelli, Charalampos S. Floudas, Gagandeep Brar, Seth M. Steinberg, Firouzeh Korangy, Tim F. Greten – 22 December 2018 – Treatment options for patients with advanced biliary tract cancer are limited.

Hung Huynh, Liek Yeow Lee, Kah Yong Goh, Richard Ong, Huai‐Xiang Hao, Alan Huang, Youzhen Wang, Diana Graus Porta, Pierce Chow, Alexander Chung – 21 December 2018 – The fibroblast growth factor (FGF) signaling cascade is a key signaling pathway in hepatocarcinogenesis. We report high FGF receptor (FGFR) expression in 17.7% (11 of 62) of hepatocellular carcinoma (HCC) models. Infigratinib, a pan‐FGFR inhibitor, potently suppresses the growth of high‐FGFR‐expressing and sorafenib‐resistant HCCs.

Myeong‐Jin Kim, Sunyoung Lee – 21 December 2018

Thomas G. Cotter, Michael R. Charlton – 20 December 2018

Bruce Wang, Sean Rudnick, Brent Cengia, Herbert L. Bonkovsky – 20 December 2018 – The acute hepatic porphyrias (AHPs) are a group of four inherited diseases of heme biosynthesis that present with episodic, acute neurovisceral symptoms. The four types are 5‐aminolevulinic acid (ALA) dehydratase deficiency porphyria, acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria. Their diagnoses are often missed or delayed because the clinical symptoms mimic other more common disorders.

Elizabeth C. Goode, Allan B. Clark, George F. Mells, Brijesh Srivastava, Kelly Spiess, William T.H. Gelson, Palak J. Trivedi, Kate D. Lynch, Edit Castren, Mette N. Vesterhus, Tom H. Karlsen, Sun‐Gou Ji, Carl A. Anderson, Douglas Thorburn, Mark Hudson, Michael A. Heneghan, Mark A. Aldersley, Andrew Bathgate, Richard N. Sandford, Graeme J. Alexander, Roger W. Chapman, Martine Walmsley, UK‐PSC Consortium, Gideon M. Hirschfield, Simon M.

Dominique Salmon‐Ceron, Pierre Nahon, Richard Layese, Valérie Bourcier, Philippe Sogni, Firouze Bani‐Sadr, Etienne Audureau, Laurence Merchadou, François Dabis, Linda Wittkop, Françoise Roudot‐Thoraval, for the ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groups – 19 December 2018 – It is widely accepted that human immunodeficiency virus (HIV) infection is a risk factor for increased severity of hepatitis C virus (HCV) liver disease.

Steven F. Solga, Marina Serper, Rebecca A. Young, Kimberly A. Forde – 18 December 2018 – Early liver transplantation for alcoholic hepatitis is a potentially life‐saving treatment. As this practice becomes increasingly common, however, the liver transplant community is taking a fresh look at a familiar challenge: best stewardship of donor organs. Herein, we examine a few basic, necessary ethical and practical concerns relevant to this indication.

Brian P. Lee, Eric Vittinghoff, Christine Hsu, Hyosun Han, George Therapondos, Oren K. Fix, David W. Victor, Deepti Dronamraju, Gene Y. Im, Michael D. Voigt, John P. Rice, Michael R. Lucey, Sheila Eswaran, Po‐Hung Chen, Zhiping Li, Haripriya Maddur, Norah A. Terrault – 18 December 2018 – Early liver transplant (LT) for alcohol‐associated disease (i.e., without a specific sobriety period) is controversial but increasingly used.